Ibrutinib Now Approved for Children With Chronic GVHD Ibrutinib Now Approved for Children With Chronic GVHD

Ibrutinib is now approved for chronic graft-vs-host disease in children aged 1 to 12 years and is available in a new oral suspension formulation.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news